Vancomycin penetration into CSF during treatment of patients receiving hemodialysis

Area of Science:

• Pharmacology
• Infectious Diseases
• Nephrology

Background:

• Staphylococcal infections, particularly those affecting the central nervous system (CNS), require effective antibiotic penetration.
• Vancomycin is a critical antibiotic for treating serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
• Patients undergoing hemodialysis often present complex treatment challenges due to altered drug pharmacokinetics.

Observation:

• This study evaluated vancomycin cerebrospinal fluid (CSF) penetration in patients on hemodialysis receiving standard treatment regimens (1 gm weekly or 750 mg twice weekly).
• CSF vancomycin concentrations were measured during three episodes of suspected or proven CNS infections in two patients.
• Drug levels were assessed against the in vitro inhibitory concentrations of the causative organisms.

Findings:

• CSF vancomycin levels ranged from <0.5 to 1.54 µg/ml.
• In only two of six CSF samples did vancomycin concentrations exceed the minimum inhibitory concentration (MIC) for the infecting staphylococcal species.
• The evaluated vancomycin hemodialysis regimens may result in marginal to subtherapeutic drug levels within the CNS.

Implications:

• Current vancomycin dosing strategies for hemodialysis patients may be insufficient for achieving adequate therapeutic concentrations in the CSF.
• Alternative dosing regimens or alternative antibiotics may be necessary for treating CNS infections in this patient population.
• Further research is warranted to optimize antibiotic therapy for CNS infections in patients with renal impairment.